Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma

Oral Oncology

Volumn 48, Issue 6, 2012, Pages 554-559

  Liu, Yu Jie ^a   Zhu, Guo Pei ^a   Guan, Xi Yin ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Assessment scale; Chemoradiation therapy; CTCAE; Nasopharyngeal carcinoma; Oral mucositis

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE SEVERITY; DYSPHAGIA; FEMALE; HUMAN; MALE; NASOPHARYNX CARCINOMA; NATIONAL CANCER INSTITUTE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS; ORAL MUCOSITIS; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE;

ADULT; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CISPLATIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RADIATION INJURIES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, INTENSITY-MODULATED; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; STOMATITIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84862811548     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2012.01.004     Document Type: Article

References (19)

1. M. Vera-Llonch, G. Oster, M. Hagiwara, and S. Sonis Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma Cancer 106 2006 329 336
2. L.S. Elting, C.D. Cooksley, M.S. Chambers, and A.S. Garden Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies Int J Radiat Oncol Biol Phys 68 2007 1110 1120
3. S.T. Sonis, L.S. Elting, D. Keefe, D.E. Peterson, M. Schubert, and M. Hauer-Jensen Perspectives on cancer therapy-induced mucosal injury - pathogenesis, measurement, epidemiology, and consequences for patients Cancer 100 2004 1995 2025
4. National Cancer Institute. Common Terminology Criteria for Adverse Events v.3.0and v.4.0 (CTCAE). Available at: http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm. Accessed June 14, 2011.
5. N.K. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, and N.J. Duez The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
6. M.T. King The interpretation of scores from the EORTC quality of life questionnaireQLQ-C30 Qual Life Res 5 1996 555 567
7. D. Osoba, G. Rodrigues, J. Myles, B. Zee, and J. Pater Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 1998 139 144
8. World Health Organization. WHO handbook for reporting results of cancer treatment. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010938. Accessed November 23, 2011.
9. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
10. S.T. Sonis, J.P. Eilers, J.B. Epstein, F.G. LeVeque, W.H. Liggett, and M.T. Mulagha Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group Cancer 85 1999 2103 2113
11. I. Guggenmoos-Holzmann The meaning of kappa: probabilistic concepts of reliability and validity revisited J Clin Epidemiol 49 1996 775 782
12. T. Byrt, J. Bishop, and J.B. Carlin Bias, prevalence and kappa J Clin Epidemiol 465 1993 423 429
13. D.V. Cicchetti, and A.R. Feinstein High agreement but low kappa: II. Resolving the paradoxes J Clin Epidemiol 43 1990 551 558
14. A.R. Feinstein, and D.V. Cicchetti High agreement but low kappa: I. The problems of two paradoxes J Clin Epidemiol 43 1990 543 549
15. D.L. Patrick, S.L. Ferketich, P.S. Frame, J.J. Harris, C.B. Hendricks, and B. Levin National Institutes of Health State-of-the-Science Conference Statement: symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002 J Natl Cancer Inst 95 2003 1110 1117
16. E. Basch, A. Iasonos, T. McDonough, A. Barz, A. Culkin, and M.G. Kris Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study Lancet Oncol 7 2006 903 909
17. L.S. Elting, D.M. Keefe, S.T. Sonis, A.S. Garden, F.K. Spijkervet, and A. Barasch Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life Cancer 113 2008 2704 2713
18. D.E. Peterson, R.-J. Bensadoun, and F. Roila On behalf of the ESMO guidelines working group. Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines Ann Oncol 21 2010 v261 v265
19. I. Gluck, K. Agbulos, D.B. Chepeha, T. Lyden, M. Haxer, and A. Popovtzer Validation of the Common Terminology Criteria for Adverse Events v3.0 (CTCAE) for dysphagia after chemo-radiotherapy (RT) for head and neck (HN) Cancer Int J Radiat Oncol Biol Phys 72 2008 S139 S140